154 related articles for article (PubMed ID: 9247842)
1. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.
Brynne N; Stahl MM; Hallén B; Edlund PO; Palmér L; Höglund P; Gabrielsson J
Int J Clin Pharmacol Ther; 1997 Jul; 35(7):287-95. PubMed ID: 9247842
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
Påhlman I; Kankaanranta S; Palmér L
Arzneimittelforschung; 2001 Feb; 51(2):134-44. PubMed ID: 11258043
[TBL] [Abstract][Full Text] [Related]
4. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
[TBL] [Abstract][Full Text] [Related]
5. Tolterodine use for symptoms of overactive bladder.
Ruscin JM; Morgenstern NE
Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
[TBL] [Abstract][Full Text] [Related]
6. Tolterodine extended-release for overactive bladder.
Chung DE; Te AE
Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs.
Andersson SH; Lindgren A; Postlind H
Drug Metab Dispos; 1998 Jun; 26(6):528-35. PubMed ID: 9616187
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
9. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
[TBL] [Abstract][Full Text] [Related]
10. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers.
Rahimy M; Hallén B; Narang P
Arzneimittelforschung; 2002; 52(12):890-5. PubMed ID: 12572529
[TBL] [Abstract][Full Text] [Related]
11. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
[TBL] [Abstract][Full Text] [Related]
13. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
14. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity.
Stahl MM; Ekström B; Sparf B; Mattiasson A; Andersson KE
Neurourol Urodyn; 1995; 14(6):647-55. PubMed ID: 8750383
[TBL] [Abstract][Full Text] [Related]
15. Clinical experiences with tolterodine.
Nilvebrant L
Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice.
Påhlman I; d'Argy R; Nilvebrant L
Arzneimittelforschung; 2001 Feb; 51(2):125-33. PubMed ID: 11258042
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Abrams P; Kaplan S; De Koning Gans HJ; Millard R
J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
[TBL] [Abstract][Full Text] [Related]
19. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
Yusup A; Akino H; Miwa Y; Oyama N; Aoki Y; Ito H; Tanase K; Matsuta Y; Nakai M; Yokoyama O
Eur J Pharmacol; 2007 Dec; 577(1-3):143-9. PubMed ID: 17904547
[TBL] [Abstract][Full Text] [Related]
20. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Schaefer W
J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
[No Abstract] [Full Text] [Related]
[Next] [New Search]